» Articles » PMID: 37475874

Single-cell Transcriptome Analysis Reveals the Clinical Implications of Myeloid-derived Suppressor Cells in Head and Neck Squamous Cell Carcinoma

Overview
Specialty Oncology
Date 2023 Jul 21
PMID 37475874
Authors
Affiliations
Soon will be listed here.
Abstract

Head and neck squamous cell carcinoma (HNSC) is the most common malignant tumor that arises in the epithelium of the head and neck regions. Myeloid-derived suppressor cells (MDSCs) are one of the tumor-infiltrating immune cell populations, which play a powerful role in inhibiting anti-tumor immune response. Herein, we employed a single-cell RNA sequencing (scRNA-seq) dataset to dissect the heterogeneity of myeloid cells. We found that tumor-associated macrophages (TAMs) and MDSCs were the most abundant myeloid cells in the microenvironment. By cell cluster deconvolution from bulk RNA-seq datasets of larger patient groups, we observed that highly-infiltrated MDSC was a poor prognostic marker for patients' overall survival (OS) probabilities. To better apply the MDSC OS prediction values, we identified a set of six MDSC-related genes (, , , , , and ) as the prognostic signature. In both training and test cohorts, MDSC-related prognostic signature showed a promising value for predicting patients' prognosis outcomes. Further parsing the ligand-receptor pairs of intercellular communications by CellChat, we found that MDSCs could frequently interact with cytotoxic T cells, TAMs, and endothelial cells. These interactions likely contributed to the establishment of an immunosuppressive microenvironment and the promotion of tumor angiogenesis. Our findings suggest that targeting MDSCs may serve as an alternative and promising target for the immunotherapy of HNSC.

Citing Articles

Inhibition of Bruton's tyrosine kinase with PD-1 blockade modulates T cell activation in solid tumors.

Schwarz E, Benner B, Wesolowski R, Quiroga D, Good L, Sun S JCI Insight. 2024; 9(21).

PMID: 39513363 PMC: 11601564. DOI: 10.1172/jci.insight.169927.


Integration of single-nuclei RNA-sequencing, spatial transcriptomics and histochemistry defines the complex microenvironment of NF1-associated plexiform neurofibromas.

Amani V, Riemondy K, Fu R, Griesinger A, Grimaldo E, de Sousa G Acta Neuropathol Commun. 2023; 11(1):158.

PMID: 37770931 PMC: 10537467. DOI: 10.1186/s40478-023-01639-1.

References
1.
Zhang F, Lin J, Zuo X, Zhuang Y, Hong C, Zhang G . Elevated transcriptional levels of aldolase A (ALDOA) associates with cell cycle-related genes in patients with NSCLC and several solid tumors. BioData Min. 2017; 10:6. PMC: 5297095. DOI: 10.1186/s13040-016-0122-4. View

2.
Ma P, Beatty P, McKolanis J, Brand R, Schoen R, Finn O . Circulating Myeloid Derived Suppressor Cells (MDSC) That Accumulate in Premalignancy Share Phenotypic and Functional Characteristics With MDSC in Cancer. Front Immunol. 2019; 10:1401. PMC: 6594197. DOI: 10.3389/fimmu.2019.01401. View

3.
Pan X, Zhang C, Wang J, Wang P, Gao Y, Shang S . Epigenome signature as an immunophenotype indicator prompts durable clinical immunotherapy benefits in lung adenocarcinoma. Brief Bioinform. 2021; 23(1). DOI: 10.1093/bib/bbab481. View

4.
Li L, Yang L, Chen X, Chen X, Diao L, Zeng Y . TNFAIP6 defines the MSC subpopulation with enhanced immune suppression activities. Stem Cell Res Ther. 2022; 13(1):479. PMC: 9509641. DOI: 10.1186/s13287-022-03176-5. View

5.
Fultang L, Panetti S, Ng M, Collins P, Graef S, Rizkalla N . MDSC targeting with Gemtuzumab ozogamicin restores T cell immunity and immunotherapy against cancers. EBioMedicine. 2019; 47:235-246. PMC: 6796554. DOI: 10.1016/j.ebiom.2019.08.025. View